Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Trimmed by Everence Capital Management Inc.

Everence Capital Management Inc. decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,740 shares of the medical equipment provider’s stock after selling 190 shares during the quarter. Everence Capital Management Inc.’s holdings in Intuitive Surgical were worth $5,084,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ISRG. Founders Financial Securities LLC raised its holdings in shares of Intuitive Surgical by 10.6% during the second quarter. Founders Financial Securities LLC now owns 2,139 shares of the medical equipment provider’s stock worth $952,000 after purchasing an additional 205 shares during the period. Simon Quick Advisors LLC lifted its holdings in Intuitive Surgical by 10.6% in the second quarter. Simon Quick Advisors LLC now owns 1,820 shares of the medical equipment provider’s stock worth $810,000 after acquiring an additional 175 shares during the last quarter. Larson Financial Group LLC boosted its stake in Intuitive Surgical by 104.3% in the second quarter. Larson Financial Group LLC now owns 476 shares of the medical equipment provider’s stock valued at $212,000 after acquiring an additional 243 shares during the period. Belpointe Asset Management LLC boosted its stake in Intuitive Surgical by 6.0% in the second quarter. Belpointe Asset Management LLC now owns 2,697 shares of the medical equipment provider’s stock valued at $1,200,000 after acquiring an additional 153 shares during the period. Finally, Stablepoint Partners LLC grew its holdings in shares of Intuitive Surgical by 2.9% during the second quarter. Stablepoint Partners LLC now owns 5,256 shares of the medical equipment provider’s stock valued at $2,332,000 after purchasing an additional 146 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Brian Edward Miller sold 2,553 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total transaction of $1,314,795.00. Following the sale, the executive vice president now owns 7,066 shares in the company, valued at $3,638,990. The trade was a 26.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 2,128 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total transaction of $1,095,920.00. Following the completion of the transaction, the senior vice president now directly owns 273 shares of the company’s stock, valued at $140,595. This represents a 88.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 48,190 shares of company stock valued at $25,012,927 over the last three months. Insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada boosted their price target on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday, October 18th. Mizuho increased their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Robert W. Baird boosted their target price on shares of Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Citigroup raised their price target on shares of Intuitive Surgical from $567.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $554.17.

Intuitive Surgical Price Performance

Shares of ISRG traded up $9.21 during mid-day trading on Friday, hitting $533.24. The company’s stock had a trading volume of 315,984 shares, compared to its average volume of 590,006. The firm has a 50-day moving average price of $532.28 and a 200 day moving average price of $489.92. Intuitive Surgical, Inc. has a fifty-two week low of $320.26 and a fifty-two week high of $556.23. The stock has a market capitalization of $189.93 billion, a price-to-earnings ratio of 85.73, a PEG ratio of 5.31 and a beta of 1.38.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.